In the TEMPO-1 trial, participants with early PD were randomly assigned to receive tavapadon 5mg or 15mg once daily or placebo.

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to ...

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...

AbbVie announced positive topline results from its Phase III TEMPO-1 trial for tavapadon as a monotherapy for early Parkinson ...

AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. Tavapadon is an investigational D1/D5 ...

Drugmaker AbbVie (ABBV) announced Thursday positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a ...

Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating on September 13. David ...

AbbVie said tavapadon met the primary endpoint in the pivotal Phase 3 fixed-dose monotherapy trial, showing a statistically significant improvement in certain measures of the disease from baseline ...

AbbVie reports positive Phase 3 results for tavapadon, a once-daily treatment for early-stage Parkinson's disease. The drug ...

AbbVie (ABBV) said its Phase 3 trial TEMPO-1 for experimental therapy Tavapadon reached main goal in Parkinson's disease.

These results back up results from the TEMPO-3 trial, which tested tavapadon as an add-on therapy to levodopa and which also ...